UK-based drug development services company Quotient Bioresearch has completed a £1.5 million expansion programme, including a new bioanalytical facility, at its site in Fordham, Cambridgeshire.
The expansion, which also incorporates new laboratories for immunoassay and cell-based work with biopharmaceuticals and biomarkers, was in response to increased demand for Quotient’s services in these areas, the company said.
According to Dr Steve Pleasance, managing director of bioanalytical services at Quotient, the laboratories at Fordham constitute “one of the world’s most extensive bioanalytical facilities”, with services spanning biomarkers, small molecules, biopharmaceuticals and antimicrobials.
The size and scope of the investment show “just how ambitious Quotient is”, Pleasance commented.
The company has been on a rapid growth track, including several acquisitions, since it was set up in 2007, originally to provide analytical and safety evaluation services and products to the bioscience and sports sectors.
In August 2009 Quotient teamed up with US testing laboratory CRL to offer global clinical laboratory capabilities to clients in the pharmaceutical, biotechnology and contract research sectors.